Biohaven’s troriluzole study for generalised anxiety disorder misses primary endpoint

This article was originally published here

This eight-week trial randomized 402 adult patients equally at more than 45 centers in the United States. In this trial, troriluzole monotherapy at 100mg twice daily did not differentiate

The post Biohaven’s troriluzole study for generalised anxiety disorder misses primary endpoint appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply